v3.22.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities    
Net loss $ (109,559) $ (79,273)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 22,381 13,334
Depreciation on property and equipment 87 43
Non-cash lease expense 831 714
Other non-cash items 0 483
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (3,809) 1,051
Accounts payable 1,383 914
Accrued expenses 16,188 2,590
Operating lease and other noncurrent liabilities (658) (687)
Net cash used in operating activities (73,156) (60,831)
Cash flows from investing activities    
Purchase of property and equipment (136) (115)
Net cash used in investing activities (136) (115)
Cash flows from financing activities    
Capital contributions 129 333
Proceeds from issuance of common stock 200,000  
Proceeds from stock options exercised 0 907
Payment of deferred offering costs 0 (1,236)
Repayment of note payable to Roivant Sciences Ltd. 0 (3,190)
Net cash provided by financing activities 200,129 382,349
Effect of exchange rate changes on cash 20 0
Net change in cash 126,857 321,403
Cash – beginning of period 400,146 100,571
Cash – end of period 527,003 421,974
Underwritten Public Offering    
Cash flows from financing activities    
Proceeds from issuance of common stock   319,783
Warrant Redemption    
Cash flows from financing activities    
Proceeds from issuance of common stock $ 0 $ 65,752

Source